13th World Clinical Biomarkers and CDx Boston 2023

Memo

The hotly anticipated 13th World Clinical Biomarkers and CDx Summit returns as the only industry-led meeting uniting 600+ senior decision makers in the biomarker and CDx field to accelerate clinically validated and affordable co-development of drug-CDx by overcoming commercialization, reimbursement and regulatory challenges in oncology and beyond to bring personalized medicine to patients faster. Whether you are working in Oncology, NASH, or Neuroscience, join 600+ Directors, Heads and VPs of Clinical Biomarkers, Translational Medicine, Precision Medicine and Companion Diagnostics together with drug and diagnostic developers, regulatory experts, payors and notified bodies for an exclusive opportunity of knowledge sharing and networking to propel your pipelines and make a marked difference for patient outcomes. URLs:Tickets: https://go.evvnt.com/1753140-2?pid=5569 Brochure: https://go.evvnt.com/1753140-3?pid=5569  Date and Time: On Tue, 05 Sep 2023 09:00 - Fri, 08 Sep 2023 18:00 Venue Details: Omni Boston Hotel at the Seaport, 450 Summer Street, Boston, Massachusetts, 02210, United States Prices:Conference Only - Vendor: USD 3799.00,Conference + Up to 5 Workshops: USD 0.00,Conference Only: USD 0.00 Speakers: Fengmin Li, Senior Staff Fellow, FDA, Carl Barrett, Vice President, Translational Science and Oncology, AstraZeneca, Eugean Jiwanmall, Senior Analyst, Research, Medical Policy and Technology Evaluation, Independence Blue Cross, Jonathan Beer, Senior Director, Translational Sciences and Diagnostics, Bristol Myers Squibb, Anthony Kanavage, IVD Product Assessment Regional Team Manager and Product Expert, TÜV SÜD Americas, Kristina McGuire, Executive Director and Head, CDx and Laboratory Operations, Regeneron, Kristy Singletary, Global Diversity, Equity and Inclusion Lead, Pfizer, Laura Dillon, Vice President, Translational Medicine and Bioinformatics, Parthenon Therapeutics, Robert H. Getzenberg, Medical Director Diagnostics, Oncology, Astellas Pharmaceuticals, Sari Pesonen, Chief Scientific Officer, Valo Therapeutics, Michael Surace, TME and IO, Translational Medicine, AstraZeneca, Sid Mathur, Executive Director, Regulatory Affairs and Companion Diagnostics, Merck and Co, Susanne Rhoades, Senior Director, Diagnostic Development, Loxo Oncology at Lilly, Thomas Defay, Deputy Head, Diagnostics Data Sciences, Genomics and Bioinformatic, Alexion Pharmaceuticals, Aastha Kohli, Senior Director, Global Regulatory Affairs, Precision Medicine Diagnostics, Gilead, Althea Lang, Project Manager, Translational Science Cancer, FNIH, Scott Shandler, Founder and CEO, Longevity Biotech, Zhen Su, Chief Executive Officer, Marengo Therapeutics, Dishant Kalra, Head, Commercial Diagnostics, Astellas Pharmaceuticals, Elaine Joseph, Director, Pharmacodiagnostic Sciences and Precision Medicine Translational Medicine, Bristol Myers Squibb, Flora Berisha, Senior Director and Head, Strategic Diagnostics Partnering and Oncology, Janssen, Heather Cohen, Director, Translational Sciences, Bicycle Therapeutics, Jeff Fill, Associate Vice President, Clinical Diagnostic Laboratory, Eli Lilly, Leonard Reyno, Executive Vice President and Chief Medical Officer, Pionyr Therapeutics, Mike Kagey, Vice President, Translational Medicine, Leap Therapeutics, Jian Wang, Head of Translational Oncology, Regulatory Science, Strategy and Excellence, AstraZeneca, Matt Houliston, Senior Director, Diagnostic Marketing and Precision Medicine, Mersana Therapeutics, Kaye Foster, Senior Advisor and Chief Executive Officer, The Boston Consulting Group , Josie Hayes, Director, Translational Oncology, Noetik, Matthew Davis, Director, Molecular Biology and Sequencing, Gritstone Bio, Marjorie Zettler, Executive Director, Clinical Science, Regor Therapeutics , Molly Martell, Director, Global Diagnostics Value and Access, Amgen, Charles Sinclair, Senior Director and Head, Translational Sciences, Flagship Pioneering, Hong Wang, Statistical Biomarker Lead, Sanofi, Satya Saxena, Director, Global Proteomics, Clinical Pharmacology and Translational Medicine, Eisai, JD Schonhoft, Senior Principal Scientist, Clinical Biomarker Lead, Repare Therapeutics, Tine Lewi, Senior Director, Platforms and Partnerships, Global Commercial Data Science, Janssen, Zheng Feng, Director, EMD Serono, Neeraj Adya, Head, Diagnostics, Genmab, Wenting Wang, Oncology Biomarker Statistics Team Lead, Sanofi, Nicole Miller, Vice President, Molecular Diagnostics, Ultragenyx, Vihanga Pahalawatta, Associate Director - Regulatory Affairs Device and Combination Products, Abbvie, Towia Libermann, Associate Professor of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Karen Weisbach, Vice President, People and Culture, Kymera Therapeutics, Juergen Scheuenpflug, Global Head, Clinical Biomarkers and CDx, Merck KGaA, Serene Yu, Director, Research Learning and Development, AstraZeneca, Minakshi Guha, LBx Strategy Lead, Companion Diagnostics, Takeda Pharmaceuticals, Pratiksha Gulati, Senior Scientist and People Enabler, Biomarkers and Bioanalytics, Roche, Mikhail Roshal, Hematopathologist, Memorial Sloan Kettering Cancer Center, Melis McHenry, Associate Director, Precision Medicine CDx, Regeneron, Dasha Kaloujskaia, Researcher, Beacon Targeted Therapies, Kamala Maddali, Rare Disease Patient and President, Health Collaborations